open access

Vol 78, No 1 (2010)
REVIEWS
Published online: 2010-01-29
Submitted: 2013-02-22
Get Citation

Chronic obstructive pulmonary disease and cardiovascular diseases

Ewa Passowicz-Muszyńska, Anna Gostkowska-Malec, Renata Jankowska, Paweł Piesiak
Pneumonol Alergol Pol 2010;78(1):28-32.

open access

Vol 78, No 1 (2010)
REVIEWS
Published online: 2010-01-29
Submitted: 2013-02-22

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Patients with COPD are at increased risk of cardiovascular diseases, osteoporosis and lung cancer. Although some of the associations between COPD and atherosclerosis may be the result of common risk factors such as smoking, epidemiological evidence suggest that impaired lung function is a risk factor for increased cardiovascular death, independent of tobacco use. This phenomenon may be related to common genetic predisposition for atherosclerosis and emphysema. Chronic obstructive pulmonary disease, like atherosclerosis, is a disease of systemic inflammation and may hasten the progression of atherosclerosis and contribute to the higher rate of death in COPD. This article reviews close relationship between COPD and cardiovascular diseases, mainly atherosclerosis. The authors also present some preliminary data suggesting a possible influence of statin therapy on the clinical course of COPD.

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Patients with COPD are at increased risk of cardiovascular diseases, osteoporosis and lung cancer. Although some of the associations between COPD and atherosclerosis may be the result of common risk factors such as smoking, epidemiological evidence suggest that impaired lung function is a risk factor for increased cardiovascular death, independent of tobacco use. This phenomenon may be related to common genetic predisposition for atherosclerosis and emphysema. Chronic obstructive pulmonary disease, like atherosclerosis, is a disease of systemic inflammation and may hasten the progression of atherosclerosis and contribute to the higher rate of death in COPD. This article reviews close relationship between COPD and cardiovascular diseases, mainly atherosclerosis. The authors also present some preliminary data suggesting a possible influence of statin therapy on the clinical course of COPD.
Get Citation

Keywords

chronic obstructive pulmonary disease; atherosclerosis; inflammation

About this article
Title

Chronic obstructive pulmonary disease and cardiovascular diseases

Journal

Advances in Respiratory Medicine

Issue

Vol 78, No 1 (2010)

Pages

28-32

Published online

2010-01-29

Bibliographic record

Pneumonol Alergol Pol 2010;78(1):28-32.

Keywords

chronic obstructive pulmonary disease
atherosclerosis
inflammation

Authors

Ewa Passowicz-Muszyńska
Anna Gostkowska-Malec
Renata Jankowska
Paweł Piesiak

References (43)
  1. Bednarek M, Maciejewski J, Wozniak M, et al. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax. 2008; 63(5): 402–407.
  2. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.org/ (2008).
  3. Chatila WM, Thomashow BM, Minai OA, et al. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008; 5(4): 549–555.
  4. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005; 127(6): 1952–1959.
  5. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008; 63(4): 306–311.
  6. Maclay JD, McAllister DA, Mills NL, et al. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology. 2007; 12(5): 634–641.
  7. McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 176(12): 1208–1214.
  8. Shifren A, Mecham RP. The stumbling block in lung repair of emphysema: elastic fiber assembly. Proc Am Thorac Soc. 2006; 3(5): 428–433.
  9. Makita H, Nasuhara Y, Nagai K, et al. Hokkaido COPD Cohort Study Group. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007; 62(11): 932–937.
  10. Guerassimov A, Hoshino Y, Takubo Y, et al. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med. 2004; 170(9): 974–980.
  11. Pyeritz RE. The Marfan syndrome. Annu Rev Med. 2000; 51: 481–510.
  12. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax. 2006; 61(7): 568–571.
  13. Gan WQ, Man SFP, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59(7): 574–580.
  14. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000; 84(2): 210–215.
  15. Sin DD, Lacy P, York E, et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170(7): 760–765.
  16. Joppa P, Petrasova D, Stancak B, et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006; 130(2): 326–333.
  17. Hansell AL, Walk JA, Soriano JB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003; 22(5): 809–814.
  18. Engström G, Wollmer P, Hedblad B, et al. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmö, Sweden. Circulation. 2001; 103(25): 3086–3091.
  19. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005; 2(1): 8–11.
  20. Anthonisen NR, Connett JE, Enright PL, et al. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002; 166(3): 333–339.
  21. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD. 2005; 2(1): 35–41.
  22. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
  23. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107(11): 1514–1519.
  24. De Reuck J, Proot P, Van Maele G. Chronic obstructive pulmonary disease as a risk factor for stroke-related seizures. Eur J Neurol. 2007; 14(9): 989–992.
  25. Arboix A, Morcillo C, García-Eroles L, et al. Different vascular risk factor profiles in ischemic stroke subtypes: a study from the "Sagrat Cor Hospital of Barcelona Stroke Registry". Acta Neurol Scand. 2000; 102(4): 264–270.
  26. Buch P, Friberg J, Scharling H, et al. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J. 2003; 21(6): 1012–1016.
  27. Huerta C, Lanes SF, García Rodríguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology. 2005; 16(3): 360–366.
  28. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004; 125(6): 2309–2321.
  29. Calverley PMA, Anderson JA, Celli B, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356(8): 775–789.
  30. Luppi F, Franco F, Beghé B, et al. Treatment of chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008; 5(8): 848–856.
  31. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc. 2008; 5(8): 857–864.
  32. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009; 9: 32–37.
  33. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47(12): 2554–2560.
  34. Søyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007; 29(2): 279–283.
  35. Ridker PM. JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003; 108(19): 2292–2297.
  36. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001; 103(9): 1191–1193.
  37. Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009; 10: 45.
  38. Kim SE, Thanh Thuy TT, Lee JiH, et al. Simvastatin inhibits induction of matrix metalloproteinase-9 in rat alveolar macrophages exposed to cigarette smoke extract. Exp Mol Med. 2009; 41(4): 277–287.
  39. Nissen SE, Nicholls SJ, Sipahi I, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006; 295(13): 1556–1565.
  40. Nicholls S, Tuzcu E, Sipahi I, et al. Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA. 2007; 297(5): 499–508.
  41. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med. 1995; 152(4 Pt 1): 1262–1267.
  42. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med. 2007; 176(8): 742–747.
  43. Khurana V, Bejjanki HR, Caldito G, et al. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest. 2007; 131(5): 1282–1288.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl